Richard B. Bartram's most recent trade in MBX Biosciences Inc. was a trade of 70,000 Stock option (right to buy) done . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MBX Biosciences Inc | Richard B. Bartram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Richard B. Bartram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 15,000 | 15,000 | - | 0 | Common Stock | |
| MBX Biosciences Inc | Richard B. Bartram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| MBX Biosciences Inc | Richard B. Bartram | Chief Financial Officer | 12 Sep 2024 | 42,578 | 42,578 | - | - | Stock Option (Right to Buy) | ||
| Esperion Therapeutics Inc | Richard B. Bartram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 37,000 | 82,751 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc | Richard B. Bartram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 18,700 | 43,852 (0%) | 0% | 0 | Common Stock |